PUBLISHED ASSESSMENT

How Influenza (Flu) Vaccines Are Made | Influenza (Flu) | CDC

This compact public record contains an assessment and source links. It does not contain article text, reader identity, browsing history, or private notes.

Historical provenance limit: this assessment has a recorded retrieval URL from before Beaconwright’s current publisher-verification boundary. It has not been reverified under the current boundary.

Open original article

The core manufacturing explanations receive substantial support from FDA and WHO materials. The principal weakness is temporal clarity: the supplied text is dated November 3, 2022 but uses later trivalent wording, while a fourth FDA-approved technology appeared in 2026. Attribution and links are present, but claim-level sourcing and revision history are incomplete.

Evidence support

Substantial (68/100)

FDA and WHO materials support the descriptions of egg-based, cell-based, and recombinant production.
FDA confirms quality-control and lot-release oversight.
The statement that vaccines target three viruses conflicts with the predominantly quadrivalent 2022–2023 context indicated by FDA records.
As of August 5, 2026, FDA approval of an mRNA influenza vaccine makes the three-technology description incomplete if read as current.

Balance & context

Substantial (71/100)

The article clearly distinguishes the three production processes and their principal inputs.
It appropriately explains candidate viruses, antigens, inactivation, and regulatory testing.
It does not adequately explain that vaccine valency and approved technologies change over time.
Manufacturing limitations and comparative tradeoffs receive little discussion.

Transparency

Mixed (58/100)

CDC authorship, a publication date, named regulators, and numerous related links are provided.
Claims are generally attributed to CDC or FDA rather than anonymous sources.
Supporting records are not linked at the individual-claim level.
The displayed November 3, 2022 date appears inconsistent with the trivalent wording adopted for later seasons, obscuring the page's revision history.

Confidence and coverage

Confidence in this analysis: Moderate confidence

Evidence coverage: Substantial coverage

Proprietary manufacturing details were not independently audited.
The page's revision history and omitted content-sources section were unavailable.
Some claims are time-dependent, creating ambiguity between the displayed 2022 date and later page revisions.

Core claims were checked against authoritative FDA and WHO sources.
Uncertainty remains about when specific portions of the supplied page text were revised.

Sources considered

FDA’s Critical Role in Ensuring Safe and Effective Flu Vaccines — Supports egg-based, cell-based and recombinant production, strain selection, quality control and lot release.
Influenza Virus Vaccine Strain Selection: 2022–23 Northern Hemisphere — Shows four-strain quadrivalent recommendations alongside trivalent options for 2022–2023, challenging the page's unqualified three-virus wording under its displayed date.
Use of Trivalent Influenza Vaccines for the 2024–2025 U.S. Influenza Season — Explains the later U.S. transition from quadrivalent to trivalent vaccines.
WHO Influenza Vaccine Composition Questions and Answers — Supports egg, cell-culture and recombinant-protein production and the role of candidate vaccine viruses.
MFLUSIVA — Documents FDA approval of an mRNA influenza vaccine on August 5, 2026, making the three-technology list outdated if read as current.

This assesses evidence and presentation; it is not an overall truth verdict.

Reassess

⚠ Paid reassessment incurs a charge. Opening this page does not start a run or incur a charge.

To request a new assessment, sign in to My library, watch this record, and select Request new assessment. Requests await separate approval and do not themselves start a paid run.

A new assessment may differ. Earlier published results remain in history.

Open My library

Assessment history

Published assessment trend

Available public snapshots only; this is not a count of all executions. Corrections may include earlier scores. Gaps mean not scored or not recorded. Different scores do not establish changed source evidence.

Evidence support — solid blueBalance & context — dashed purpleTransparency — dotted green

Reassess ⚠

Recorded public scores (0–100)
Date	Evidence support	Balance & context	Transparency
2026-09-12 (current)	68	71	58